Compare DexCom, Inc. (DXCM) vs ServiceNow Inc (NOW) Price & Performance

DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.

The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.

ServiceNow (NOW) trades at $104.85, down 5.76% over the past day, with a neutral technical signal. The stock shows strong fundamentals, with revenue growing from $7.2B in 2022 to $13.3B in 2025 and a robust gross profit margin of 76.56%. Recent earnings have mostly beaten expectations, and the company maintains positive operating cash flow. Analyst sentiment is overwhelmingly bullish, with an 85.51% buy rating and a consensus price target of $137.52, suggesting significant upside potential from current levels.

The outlook for NOW is positive, driven by its leadership in enterprise AI solutions and consistent financial performance. Investment opportunities include exposure to high-growth AI markets and strong cash generation. Key risks involve elevated valuation multiples, competitive pressures in the SaaS sector, and execution challenges in sustaining growth. The stock presents a compelling case for growth-oriented investors, though its high P/E ratio warrants caution amid market volatility.